Microvast Holdings announces departure of chief financial officer
Anthony J. Recupero, the President of Commercial Operations at SI-BONE, Inc. (NASDAQ:SIBN), recently sold shares of the company’s common stock valued at approximately $160,732. The transactions, which took place on February 18, involved selling a total of 9,531 shares at prices ranging from $16.3854 to $17.3682 per share. The stock, currently trading at $17.84, has shown impressive momentum with a 9.82% gain in the past week. According to InvestingPro data, analysts maintain a strong buy consensus with price targets ranging from $15 to $32.
These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units, as indicated in the SEC filing. Following these transactions, Recupero maintains direct ownership of 287,866 shares of SI-BONE stock. With a market capitalization of $748.6 million, SI-BONE maintains strong financial health, earning a "GREAT" overall score from InvestingPro. Subscribers can access 6 additional ProTips and a comprehensive Pro Research Report for deeper insights into the company’s fundamentals and growth prospects.
In other recent news, Piper Sandler analysts provided insights into several healthcare companies ahead of a major investor conference. They expressed optimism for companies like ATEC, ATRC, and KIDS, expecting positive fiscal year outlooks. Analysts anticipate potential upside for FNA and SIBN, which are likely to issue full-year guidance with their Q4 earnings. MASI was highlighted as a top idea, with management confident in surpassing Q4 projections and 2025 consensus estimates. MMSI is expected to continue its trend of quarterly beats, potentially aided by the approval of WRAPSODY. NVCR’s revenue growth in glioblastoma multiforme is anticipated to maintain momentum into Q4. INSP is projected to exceed Q4 expectations and provide comfortable 2025 guidance. NARI is expected to report a Q4 beat and guide to 16-19% revenue growth for 2025. Meanwhile, ISRG is anticipated to report strong quarterly results, though its initial procedure volume guidance for 2025 might be conservative.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.